Univ. of Wash.-spinout Icosavax raises $100M to fund vaccine development technology
GeekWire
APRIL 7, 2021
Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. Simpson was formerly the CEO of PvP Biologics, another IPD spinout, which he oversaw from the company’s launch through its sale to the pharmaceutical company Takeda. Icosavax Photo).
Let's personalize your content